Skip to main content
SpringerLink
Log in

Investigational Therapy in Acute Myeloid Leukemia: 2001

  • Conference paper
Acute Leukemias IX

Part of the book series: Haematology and Blood Transfusion Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 41))

  • 136 Accesses

Abstract

Current treatment for adults with acute myeloid leukemia (AML) generally includes cytosine arabinoside (ara-C) and an anthracycline or anthracycline derivative (daunorubicin, idarubicin, mitoxantrone). Improved survival for subgroups of AML patients has been realized with the use of high-dose ara-C, particularly in younger patients with inv(16) and t(8;21) karyotypes [1] and with all trans retinoic acid (ATRA) in patients with a t(15;17) translocation [2]. Effective therapy for older patients (above age 60), those with a prior myelodysplastic syndrome (MDS), and for patients with unfavorable cytogenetic changes (-5,-7), has not yet been found [3]. Accordingly, there continues to be a need to investigate new treatments. The development of anti-leukemic therapy has followed three broad strategies;

  1. 1.

    enhancing the efficacy of existing active drugs by pharmacomodulation

  2. 2.

    finding new chemotherapeutic agents

  3. 3.

    identifying non- chemotherapeutic modalities of treatment

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Strout MP; Marcucci G; Caligiuri MA; Bloomfield CD. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol 1999 Jun; 78 (6): 251 – 64.

    Article  PubMed  CAS  Google Scholar 

  2. Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Ogden A; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH. Alltrans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997 Oct 9; 337 (15): 1021 – 8.

    Article  PubMed  CAS  Google Scholar 

  3. Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997 May 1; 89 (9): 3323 – 9.

    PubMed  CAS  Google Scholar 

  4. Chelliah J; Freemerman AJ; Wu-Pong S; Jarvis WD; Grant S. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc. Biochem Pharmacol 1997 Sep 1; 54 (5): 563 – 73.

    Article  PubMed  CAS  Google Scholar 

  5. Tang L; Boise LH; Dent P; Grant S. Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) Biochem Pharmacol 2000 Nov 15; 60 (10): 1445 – 56.

    CAS  Google Scholar 

  6. Cotter FE Antisense therapy of hematologic malignancies. Semin Hematol 1999 Oct; 36 (4 Suppl 6): 9 – 14.

    PubMed  CAS  Google Scholar 

  7. Grant S; Cragg L; Feldman E; Andreef M; Roberts J; Tombes M; Winning M. Phase I trial of highdose 1-B-D-arabinofurannosylcyto sine (Hidac) and bryostatin 1 in patients with refractory acute myelogenous or lymphoblastic leukemai and CML-myeloid blast crisis. Blood Volume 96 (suppl) no 11 abstr 1396 Nov 2000

    Google Scholar 

  8. Beran M; Estey E; O’Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 1998 Nov; 31 (5-6): 521 – 31.

    PubMed  CAS  Google Scholar 

  9. Vey N; Kantarjian H; Beran M; O’Brien S; Cortes J; Koller C; Estey E. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest New Drugs 1999; 17 (1): 89 – 95.

    Article  PubMed  CAS  Google Scholar 

  10. Joto N; Ishii M; Minami M; Kuga H; Mitsui 1; Tohgo A. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer 1997 Aug 7; 72 (4): 680 – 6.

    Article  PubMed  CAS  Google Scholar 

  11. Adams J; Palombella VJ; Elliott PJ Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000 May; 18 (2): 109 – 21.

    Article  PubMed  CAS  Google Scholar 

  12. Giles FJ; Cortes JE; Baker SD; Thomas DA; O’Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced Leukemia. J Clin Onco12001 Feb 1;19(3):762–771.

    PubMed  CAS  Google Scholar 

  13. Sievers EL; Appelbaum FR; Spielberger RT; Forman SJ; Flowers D; Smith FO; Shannon-Dorcy K; Berger MS; Bernstein ID Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999 Jun 1; 93 (11): 3678 – 84.

    PubMed  CAS  Google Scholar 

  14. Sievers EL; Larseon RA; Estey E: Efficacy and safety of CMA-676 in patients with AML in first relapse. Blood 94 (suppl 1 ) 696a (abstr) 1999.

    Google Scholar 

  15. Caron PC; Scheinberg DA Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leuk Lymphoma 1993;11 Suppl 2(5):1–6.

    Article  PubMed  Google Scholar 

  16. Feldman E; Kalaycio M; Schulman P; Frankel S; Weiner L; Schwarzberg L; Velex-Garcia E; Jurcic J; Scheinberg D; Wedel N. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia: preliminary report of a phase II study. Proceeding of ASCO 1999 abstr 12

    Google Scholar 

  17. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, how C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000 Feb; 18 (4): 927 – 41.

    PubMed  CAS  Google Scholar 

  18. Lancet J; Rosenblatt J; Liesveld J; End D; Hovak I; Ange D, Rosell K; Petronio S; Smith A; Karp J. Use of farnesyl transferase inhibitor R11577 in relapsed and refractory acute leukemias: preliminary results of a phase I trial. Proceedings ASCO 2000 abstr 5b.

    Google Scholar 

  19. Padro T; Ruiz S; Bieker R; Burger H; Steins M; Kienast J; Buchner T; Berdel WE; Mesters RM Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000 Apr 15; 95 (8): 2637 – 44.

    PubMed  CAS  Google Scholar 

  20. Larrivee B; Karsan A. signaling pathways induced by vascular endothelial growth factor (review). Int J Mol Med 2000 May; 5 (5): 447 – 56.

    PubMed  CAS  Google Scholar 

  21. Dias S; Hattori K; Zhu Z; Heissig B; Choy M; Lane W; Wu Y; Chadburn A; Hyjek E; Gill M; Hicklin DJ; Witte L; Moore MA; Rafii S Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000 Aug; 106 (4) 511 – 21

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Weill Medical College of Cornell University, 525 East 68th street, NewYork, NY. 10021, USA

    E. J. Feldman

Authors
  1. E. J. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinikum Grofihadern Med. Klinik III, Ludwig-Maximilians-Universität, Marchioninistr. 15, 81377, München, Germany

    Wolfgang Hiddemann , Torsten Haferlach  & Michael Unterhalt ,  & 

  2. Department of Internal Medicine A, University of Münster, Albert-Schweitzer-Str. 33, 48149, Münster, Germany

    Thomas Büchner

  3. Department of Pediatric Hematology/Oncologic, University of Münster, Albert-Schweitzer-Str. 33, 48149, Münster, Germany

    Jörg Ritter

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Feldman, E.J. (2003). Investigational Therapy in Acute Myeloid Leukemia: 2001. In: Hiddemann, W., Haferlach, T., Unterhalt, M., Büchner, T., Ritter, J. (eds) Acute Leukemias IX. Haematology and Blood Transfusion Hämatologie und Bluttransfusion, vol 41. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59358-1_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59358-1_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63949-4

  • Online ISBN: 978-3-642-59358-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation